THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, March 18, 2021
The Novavax vaccine is a two-dose vaccine that differs from the Moderna and Pfizer vaccines in that it does not use mRNA technology. As a result, the Novavax COVID vaccine does not require ultra-cold storage, which could make distribution easier once it is licensed for pandemic use in an emergency.
FREMONT, CA: Wake Research, an integrated national network of clinical investigative sites and one of North America’s leading providers of Phase I-IV clinical trials, was identified as a Top Enroller of patient volunteers by Novavax, a Maryland-based biotechnology firm, in their COVID-19 Phase III vaccine clinical trial.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Featured in Pharma Tech Outlooks’s ‘Top 10 CROs’, Wake Research has helped lead the nation's efforts to provide high-quality trial data on COVID vaccines to help many vaccines get the FDA's greenlight after hosting the official launch of Operation Warp Speed with Vice President Mike Pence during his visit to the Research Triangle in 2020. In the Novavax vaccine trial, Wake Research vaccinated over 2,000 patients, and over 6,000 patients through various COVID vaccine trials, including those by Moderna, Pfizer, and Johnson & Johnson.
“This accomplishment would not have been possible without the dedication of our staff who applied their experience and expertise to make sure quality data was collected and patients’ safety was ensured at every step of the process,” said Marieke Cajal-Berman, Director of Patient Engagement, Wake Research. “We were truly overwhelmed by the tremendous response from our community and the number of volunteers coming forward to help with this historic medical advancement.”
“Studies are ongoing as more vaccines are still needed to have enough doses available for all, and to ensure immunity against the new variants. We hope volunteers will continue to answer the call to action. We are all in this together, and we look forward to continuing to work together with all who are involved in these invaluable clinical research efforts.”
Despite the fact that Novavax vaccine trials began in late December in the United States, early findings and international studies show that the Novavax COVID vaccine candidate is already promising. Official results from U.S. trials are still pending, but in a 15,000-person study in the United Kingdom, the Novavax vaccine was found to be 89.3 percent successful. The Novavax clinical trial possibly included participants who had been exposed to some of the newer coronavirus strains due to its later start. Wake Research physicians are still positive about the Novavax COVID vaccine. The outlook is positive, according to Matthew Hong, MD, principal investigator at Wake Research's Raleigh site, who told local news outlet CBS-17 that the Novavax vaccine is also expected to get FDA approval.
“Companies and governments around the world came together with scientists, physicians, and patients, working tirelessly to stop this pandemic, and we are honored to be a part of ongoing efforts to stop the coronavirus,” states Ella Grach, MD, Chief Executive Officer, Wake Research. “We utilize a proven, highly effective multi-faceted approach to patient engagement, and we strive to continually improve upon our already successful system of resources, expertise, and strategies for optimum success in patient enrollment.” “Our mission is to enhance healthcare by preventing diseases and accelerating cures through clinical trials,” she adds.
The Novavax vaccine is a two-dose vaccine that differs from the Moderna and Pfizer vaccines in that it does not use mRNA technology. As a result, the Novavax COVID vaccine does not require ultra-cold storage, which could make distribution easier once it is licensed for pandemic use in an emergency. Furthermore, the Novavax vaccine employs cutting-edge technology that builds on the technology used in conventional flu vaccines and other anti-virus vaccines while also targeting the coronavirus. The Novavax vaccine contains a spike protein that stimulates the human immune system, allowing it to combat the coronavirus' spike protein. In addition, the Novavax vaccine includes a natural immunity booster extracted from tree bark that increases immunity by 3-10 times over the vaccine alone.
More in News